Consensus Chemed Corporation

Stocks

CHE

US16359R1032

Healthcare Facilities & Services

Market Closed - NYSE Other stock markets 16:00:02 2026-06-29 EDT			5-day change	1st Jan Change
459.90 ^USD	-0.73%		+5.42%	+7.49%

06-10	Chemed Insider Sold Shares Worth $602,554, According to a Recent SEC Filing	MT
06-08	Chemed Unit Acquires Franchise Territory in Texas	MT

Evolution of the Average Target: Chemed Corporation

Evolution of the Target Price: Chemed Corporation

Changes in Analyst Recommendations: Chemed Corporation

f29085f43ea601e538d602ded.mKEaLmJK5uIuTD2UZhJTRzy8puqZaLplFVPYFf9ZFbs.qtJOZAkdrr1CdEn7B3s6F0zex6vrHtwLIwqud6wUbe_8xSplLhuq2mgfTg~014933baacbfaf67b7a6822448b550a8

Analysts' recommendations: Chemed Corporation

04-27	Chemed' VITAS Continues to Build Momentum, RBC Says	MT
04-27	RBC Lifts Price Target on Chemed to $436 From $422, Keeps Sector Perform Rating	MT
03-31	Chemed Can Unlock Value From Roto-Rooter Unit, Oppenheimer Says	MT
02-27	Chemed's Roto-Rooter Unit Faces Cost Pressures as Hospice Segment Looks Bullish, RBC Says	MT
02-27	Oppenheimer Adjusts Price Target on Chemed to $500 From $580, Maintains Outperform Rating	MT
02-27	RBC Downgrades Chemed to Sector Perform From Outperform, Cuts Price Target to $422 From $572	MT
01-22	Jefferies Downgrades Chemed to Hold From Buy, Adjusts Price Target to $475 From $550	MT
01-22	Analyst recommendations: Datadog, Albemarle, Halliburton, Netflix…
11-10	RBC Lowers Price Target on Chemed to $572 From $589, Keeps Outperform Rating	MT
11-04	Analysts recommendations: Apple, Comcast, Crocs, Eli Lilly, Palantir…
25-09-02	Analysts recommendations: Acuity, Block, Elf Beauty, Fortinet, Nvidia…
25-09-02	Jefferies Upgrades Chemed to Buy From Hold, Adjusts Price Target to $550 From $490	MT
25-07-31	RBC Lowers Price Target on Chemed to $589 From $640, Keeps Outperform Rating	MT
25-07-25	Jefferies Initiates Chemed at Hold With $500 Price Target	MT
25-06-30	RBC Cuts Price Target on Chemed to $640 From $674, Keeps Outperform Rating	MT
25-04-28	RBC Lifts Price Target on Chemed to $674 From $667, Keeps Outperform Rating	MT
25-03-14	RBC Raises Price Target on Chemed to $667 From $633, Keeps Outperform Rating	MT
24-05-21	RBC Cuts Price Target on Chemed to $697 From $712, Maintains Outperform Rating	MT
24-04-26	Chemed Reports 'Soft' Q1 as Roto-Rooter Continues to Face Pressure, Oppenheimer Says	MT
24-03-04	RBC Boosts Price Target on Chemed to $712 From $604, Expects 'Strong' VITAS Momentum to Continue in 2024; Outperform Kept	MT
24-02-29	Oppenheimer Raises Chemed Price Target to $650 From $625, Maintains Outperform Rating	MT
24-01-17	Oppenheimer Adjusts Chemed Price Target to $625 From $590, Maintains Outperform Rating	MT
23-10-30	RBC Raises Price Target on Chemed to $604 From $576, Keeps Outperform Rating	MT
23-07-31	RBC Cuts Price Target on Chemed to $576 From $610, Maintains Outperform Rating	MT
23-07-27	Oppenheimer Adjusts Chemed Price Target to $590 From $610, Maintains Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CHEMED CORPORATION					-3.62%
	CVS HEALTH CORPORATION					+1%
	HCA HEALTHCARE, INC.					+27.73%
	FRESENIUS SE & CO. KGAA					+36.17%
	QUEST DIAGNOSTICS INCORPORATED					+6.46%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+27.13%
	TENET HEALTHCARE CORPORATION					+28.67%
	REDE D'OR SÃO LUIZ S.A.					+39.67%
	DAVITA INC.					-10.75%
	FRESENIUS MEDICAL CARE AG					+6.94%
	Average					+15.94%
	Weighted average by Cap.					+14.54%